Company Overview and News

53
OPGN / OpGen, Inc. FORM 8-K (Current Report)

2018-06-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
OPGN

68
OPGN / OpGen, Inc. FORM 8-K (Current Report)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
OPGN

46
OPGN / OpGen, Inc. PROSPECTUS SUPPLEMENT (Prospectus)

2018-05-23 sec.gov
Prospectus Supplement No. 1 Filed Pursuant to Rule 424(b)(3)
OPGN

50
OPGN / OpGen, Inc. PROSPECTUS SUPPLEMENT (Prospectus)

2018-05-23 sec.gov
Prospectus Supplement No. 1 Filed Pursuant to Rule 424(b)(3)
OPGN

49
OpGen's (OPGN) CEO Evan Jones on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Welcome to the OpGen First Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded Tuesday, May 8, 2018.
TMO OPGN

51
OPGN / OpGen, Inc. FORM 8-K (Current Report)

2018-05-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
OPGN

44
OpGen Announces Date of First Quarter 2018 Financial Results Conference Call

2018-05-01 globenewswire
GAITHERSBURG, Md., May 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the Company will report financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Tuesday, May 8, 2018. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern time to discuss the Company’s financial results and business progress.
OPGN

57
OPGN / OpGen, Inc. DEFINITIVE 14A ADDITIONAL MATERIALS

2018-04-30 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
OPGN

56
OPGN / OpGen, Inc. DEFINITIVE 14A

2018-04-30 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
OPGN

44
OpGen Highlights Acuitas® Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug Resistance Gene Profiles at ECCMID

2018-04-24 globenewswire
GAITHERSBURG, Md., April 24, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented analytical validation results for the Acuitas® AMR Gene Panel u5.47 (RUO) for detection of multi-drug resistant pathogens and antibiotic resistance genes and the use of test results to predict antibiotic resistance using the bioinformatics capabilities of the Acuitas Lighthouse® Software.
OPGN

44
OpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International Operations

2018-04-19 globenewswire
GAITHERSBURG, Md., April 19, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification and treatment of bacteremia and fungemia in hospital intensive care units in Colombia. The study showed significant improvement in survival and reductions in antibiotic usage for patients receiving the OpGen rapid diagnostic test.
OPGN

44
OPGN / OpGen, Inc. POST-EFFECTIVE AMENDMENT NO 1 TO FORM S-1

2018-04-04 sec.gov
As filed with the Securities and Exchange Commission on April 4, 2018 File No. 333-218392
OPGN

45
OPGN / OpGen, Inc. POST-EFFECTIVE AMENDMENT NO 1 TO FORM S-1

2018-04-04 sec.gov
As filed with the Securities and Exchange Commission on April 4, 2018 File No. 333-222140
OPGN

45
OPGN / OpGen, Inc. FORM S-8

2018-03-29 sec.gov
As filed with the Securities and Exchange Commission on March 29, 2018 Registration No. 333-______
OPGN

45
OPGN / OpGen, Inc. 10-K (Annual Report)

2018-03-29 sec.gov
opgn-10k_20171231.htm UNITED STATES
OPGN

OPGN : OpGen Stock Analysis and Research Report

2017-11-03 - Asif

OpGen was incorporated in Delaware in 2001. The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark. The Company operates in one business segment. OpGen is a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. The Company is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The Company’s molecular diagnostics and informatics...

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 68373L208